Showing 1751-1760 of 2105 results for "".
- Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Periodhttps://practicalneurology.com/news/early-treatment-of-clinically-isolated-syndrome-with-interferon-1b-shows-benefit-over-a-15-year-period/2468814/Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of diagnosis.) After 15 years, patients who were treated upon diagnosis of CIS (n = 161) or within 2 years of diagnosis (n = 100
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Four-Year Clarity-AD Data Show Slower Clinical Decline with Leqembi Treatmenthttps://practicalneurology.com/news/four-year-clarity-ad-data-show-slower-clinical-decline-with-leqembi-treatment/2475914/According to new 48-month data from the Clarity-AD (NCT03887455) open-label extension (OLE) study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), individuals with early Alzheimer disease (AD) who received continuous treatment with Leqembi (lecanemab-i
- Vagus Nerve Stimulation Paired With Rehabilitation Yields Sustained Upper Limb Recovery in Individuals With Strokehttps://practicalneurology.com/news/vagus-nerve-stimulation-paired-with-rehabilitation-yields-sustained-upper-limb-recovery-in-individuals-with-stroke/2474624/According to post hoc analysis of the VNS-REHAB clinical trial (NCT03131960), vagus nerve stimulation (VNS) paired with upper extremity (UE) rehabilitation showed significant improvements in UE impairment, activity, and quality-of-life (QoL) measures in individuals who experienced ischemic stroke
- The FDA Approved a New Oral, As-Needed Tablet for Acute Migraine Treatmenthttps://practicalneurology.com/news/the-fda-approved-a-new-oral-as-needed-tablet-for-acute-migraine-treatment/2473775/The Food and Drug Administration (FDA) has approved Symbravo (meloxicam and rizatriptan; Axsome Therapeutics, New York, NY) for the acute treatment of adults diagnosed with migraine with or without aura. Symbravo, previously known as AXS-07, is a single-dose, oral medication for use as-needed. Ax
- Uplizna Treatment for NMOSD Shows Sustained Clinical Benefit Over 4 Years According to Full N-MOmentum Datahttps://practicalneurology.com/news/uplizna-treatment-for-nmosd-shows-sustained-clinical-benefit-over-4-years-according-to-full-n-momentum-data/2470476/New end-of-study results from the N-MOmentum clinical trial (NCT02200770) which included data from the randomized controlled period and the open-label extension periods were published in The Lancet Neurology. According to the findings, long-term treatment with Uplizna (inebilizumab-cdon;
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Elfabrio Shows Comparable Efficacy to Agalsidase Beta at 2 Years as Treatment for Fabry Diseasehttps://practicalneurology.com/news/elfabrio-shows-comparable-efficacy-to-agalsidase-beta-at-2-years-as-treatment-for-fabry-disease/2470380/New results from the phase 3 BALANCE clinical trial (NCT02795676), published in the Journal of Medical Genetics, demonstrated that Elfabrio (pegunigalsidase alfa-iwxj; Chiesi Global Rare Diseases, Boston, MA; Portalix BioTherapeutics, Carmiel, Israel) was well-tolerated and has comparabl
- 81% of Infants with SMA Treated with Evrysdi for 1 Year Able to Sit Independently According to RAINBOWFISH Studyhttps://practicalneurology.com/news/81-of-infants-with-sma-treated-with-evrysdi-for-1-year-able-to-sit-independently-according-to-rainbowfish-study/2470318/According to an analysis of data from the RAINBOWFISH clinical trial (NCT03779334), treatment with Evrysdi (risdiplam; Genentech, South San Francisco, CA) in infants with presymptomatic spinal muscular atrophy (SMA) resulted in favorable outcomes. The new results were presented at the 28th World
- Stroke Risk Increases Significantly After Head Injury, 30-Year Study Findshttps://practicalneurology.com/news/stroke-risk-increases-significantly-after-head-injury-30-year-study-finds/2470292/People who have experienced traumatic brain injury (TBI), regardless of severity, are at significantly greater risk of ischemic stroke, according to a study presented at the 148th Annual Meeting of the American Neurological Association. The study also found that the risk of ischemic stroke increa